微小肝癌早期诊断关键分子的研究进展  

Study on the key molecules in early diagnosis of micro hepatocellular carcinoma

作　　者：杨静[1] 曹宪炳 连镇炎 周旭洋 张诗雨 曾宁 方驰华 YANG Jing;CAO Xianbing;LIAN Zhenyan;ZHOU Xuyang;ZHANG Shiyu;ZENG Ning;FANG Chihua(The Second Clinical Medical College,Southern Medical University,Guangzhou 510282,China;Digital-medicine Clinical Engineering Technology Research Center of Guangdong,Guangzhou 510282,China)

机构地区：[1]南方医科大学第二临床医学院,广东广州510282 [2]广东省数字医学临床工程技术研究中心,广东广州510282

出　　处：《分子影像学杂志》2020年第4期621-624,共4页Journal of Molecular Imaging

基　　金：南方医科大学2019年校级大学生创新训练计划项目资助(201912121241);“十二五”国家高技术研究发展(863)计划(2012AA021105);“十三五”国家重点研发计划数字诊疗装备研发重点专项(2016YFC0106500);NSFC-广东联合基金项目(U1401254);国家自然科学基金重大仪器项目(81627805);广州市科技计划(201604020144);广东省科技计划(2016ZC0082)。

摘　　要：肝癌是消化系统的常见恶性肿瘤之一,因大多数患者在肝癌早期并无临床症状,在就诊时已多是晚期,死亡率高特点决定了早期诊断和早期治疗是提高生存率最有效手段。如何提高微小肝癌的早期诊断成为我们亟待解决的重要问题,而微小肝癌早期新生血管关键分子则成为早期诊断至关重要的一步。本文通过查阅近几年国内外相关文献,对部分微小肝癌早期诊断关键分子-Prox1、Glypican-3、上皮细胞黏附因子、趋化因子受体4的研究现状和不足进行综述,旨在为微小肝癌的早期筛查和诊断提供的新方向及思路。Liver cancer is one of the common malignant tumors of the digestive system.Most patients have no clinical symptoms in the early stages of liver cancer and are mostly advanced at the time of consultation.The high mortality rate determines that early diagnosis and early treatment are the most effective methods to improve survival rate.Therefore,how to improve the early diagnosis of minimal liver cancer has become an urgent issue that we need to solve.The key molecules of early neovascularization of micro hepatocellular carcinoma have become a very important step in early diagnosis.Therefore,by reviewing relevant domestic and foreign literature in recent years,this article studied four key molecules of early diagnosis of micro hepatocellular like carcinoma-Prox1,Glypican-3,EpCAM,CXCR4.The current situation and deficiencies were reviewed in order to provide new directions and ideas for the early screening and diagnosis of minimal liver cancer.

关 键 词：微小癌灶 早期诊断 肝癌 关键分子 肿瘤标志物 

分 类 号：R735.7[医药卫生—肿瘤]